Sign In
Buy BYSI
$1.74
+0.0400 (+2.35%)
At Close: Jun 03, 2026
BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update
11:00am, Thursday, 30'th Apr 2020
- FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN - -.
BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update
11:00am, Thursday, 30'th Apr 2020
- FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN - ...
Bank of New York Mellon Corp Grows Stake in Beyondspring Inc (NASDAQ:BYSI)
08:52am, Thursday, 30'th Apr 2020
Bank of New York Mellon Corp increased its holdings in shares of Beyondspring Inc (NASDAQ:BYSI) by 13.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchan
Beyondspring (NASDAQ:BYSI) Rating Reiterated by HC Wainwright
07:20am, Thursday, 30'th Apr 2020
Beyondspring (NASDAQ:BYSI)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Wednesday, TipRanks reports. They currently have a $30.00 pr
Beyondspring (BYSI) Gets a Buy Rating from H.C. Wainwright
03:09pm, Wednesday, 29'th Apr 2020
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Beyondspring (BYSI) today and set a price target of $30.00. The company's shares
FDA on board with endpoint change in study of BeyondSpring's Plinabulin
02:39pm, Wednesday, 29'th Apr 2020
BeyondSpring (BYSI +4.5%) announces that the FDA has signed off on changing the primary endpoint of its Phase 3 clinical trial, Study 106, evaluating lead drug Plinabulin for the prevention of chemo-i
The Potential for Superior and Rapid Onset Protection from Infection with Plinabulin-G-CSF Combination Marks First Significant Enhancement in Preventing Neutropenia in 30 Years
FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study
12:00pm, Wednesday, 29'th Apr 2020
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a New York-based global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today a
Beyondspring (NASDAQ:BYSI) Downgraded to "Hold" at Zacks Investment Research
06:58am, Saturday, 25'th Apr 2020
Zacks Investment Research lowered shares of Beyondspring (NASDAQ:BYSI) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports. According to Z
BeyondSpring to Host Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update Conference Call on April 30, 2020
12:00pm, Thursday, 23'rd Apr 2020
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will
Beyondspring (NASDAQ:BYSI) Rating Increased to Buy at Zacks Investment Research
05:48am, Wednesday, 22'nd Apr 2020
Beyondspring (NASDAQ:BYSI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Monday, Zacks.com reports. The firm presently has a $14
Beyondspring Inc (NASDAQ:BYSI) Expected to Post Earnings of -$0.56 Per Share
10:32am, Saturday, 18'th Apr 2020
Wall Street analysts expect Beyondspring Inc (NASDAQ:BYSI) to report earnings per share (EPS) of ($0.56) for the current quarter, Zacks reports. Zero analysts have issued estimates for Beyondspring’
Beyondspring (NASDAQ:BYSI) and Prestige Consumer Healthcare (NASDAQ:PBH) Critical Review
06:34am, Friday, 17'th Apr 2020
Beyondspring (NASDAQ:BYSI) and Prestige Consumer Healthcare (NYSE:PBH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the streng
Beyondspring (NASDAQ:BYSI) Rating Lowered to Hold at Zacks Investment Research
09:42am, Thursday, 16'th Apr 2020
Beyondspring (NASDAQ:BYSI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports. According to Zacks, “BeyondS
Beyondspring (NASDAQ:BYSI) Rating Increased to Buy at Zacks Investment Research
05:36am, Sunday, 12'th Apr 2020
Beyondspring (NASDAQ:BYSI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday, Zacks.com reports. The brokerage currently
